LESAKA TECHNOLOGIES, INC.
Unaudited Condensed Consolidated Statements of Cash Flows
7
Three months ended
September 30,
2025
2024
(In thousands)
Cash flows from operating activities
Net loss
$
(4,414)
$
(4,542)
Depreciation and amortization
12,894
6,276
Movement in allowance for doubtful accounts receivable and finance loans receivable
2,606
1,499
Earnings from equity-accounted investments (Note 6)
-
(27)
Fair value adjustment related to financial liabilities
(1)
190
Interest payable
(107)
1,693
Facility fee amortized
78
69
Net loss on disposal of equity-accounted investments (Note 6)
584
-
Profit on disposal of property, plant and equipment
(30)
(27)
Stock-based compensation charge (Note 13)
1,861
2,377
Changes in net working capital
(Increase) Decrease in accounts receivable and other receivables
(1,230)
7,692
Increase in finance loans receivable
(6,903)
(1,590)
(Decrease) Increase in inventory
5,148
(889)
Decrease in accounts payable and other payables
(594)
(17,177)
Increase in taxes payable
512
765
Decrease in deferred taxes
(1,481)
(446)
Net cash provided by (used in) operating activities
8,923
(4,137)
Cash flows from investing activities
Capital expenditures
(3,980)
(3,965)
Proceeds from disposal of property, plant and equipment
452
850
Acquisition of intangible assets
(1,139)
(173)
Net change in settlement assets
4,206
3,570
Net cash (used in) provided by investing activities
(461)
282
Cash flows from financing activities
Proceeds from bank overdraft (Note 9)
27,974
23,893
Repayment of bank overdraft (Note 9)
(40,661)
(31,028)
Long-term borrowings utilized (Note 9)
2,763
774
Repayment of long-term borrowings (Note 9)
(1,148)
(5,472)
Non-refundable deal origination fees (Note 9)
(33)
-
Net change in settlement obligations
(3,633)
(3,648)
Net cash used in financing activities
(14,738)
(15,481)
Effect of exchange rate changes on cash
1,921
3,226
Net decrease in cash, cash equivalents and restricted cash
(4,355)
(16,110)
Cash, cash equivalents and restricted cash – beginning of period
76,639
65,919
Cash, cash equivalents and restricted cash – end of period (Note 15)
$
72,284
$
49,809
See Notes to Unaudited Condensed Consolidated Financial Statements